DE60132343D1 - Fgf-2 zur behandlung von erkrankungen der peripheralen arterien - Google Patents

Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Info

Publication number
DE60132343D1
DE60132343D1 DE60132343T DE60132343T DE60132343D1 DE 60132343 D1 DE60132343 D1 DE 60132343D1 DE 60132343 T DE60132343 T DE 60132343T DE 60132343 T DE60132343 T DE 60132343T DE 60132343 D1 DE60132343 D1 DE 60132343D1
Authority
DE
Germany
Prior art keywords
fgf
artery disease
peripheral artery
compositions
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60132343T
Other languages
English (en)
Other versions
DE60132343T2 (de
Inventor
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE60132343D1 publication Critical patent/DE60132343D1/de
Application granted granted Critical
Publication of DE60132343T2 publication Critical patent/DE60132343T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60132343T 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien Expired - Fee Related DE60132343T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US213504P 2000-06-22
US26457201P 2001-01-26 2001-01-26
US264572P 2001-01-26
US27654901P 2001-03-16 2001-03-16
US276549P 2001-03-16
US886856 2001-06-21
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease
PCT/US2001/019978 WO2001098346A2 (en) 2000-06-22 2001-06-22 Methods and compositions for the treatment of peripheral artery disease

Publications (2)

Publication Number Publication Date
DE60132343D1 true DE60132343D1 (de) 2008-02-21
DE60132343T2 DE60132343T2 (de) 2008-12-24

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132343T Expired - Fee Related DE60132343T2 (de) 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Country Status (8)

Country Link
US (3) US20020115603A1 (de)
EP (1) EP1324766B1 (de)
JP (1) JP2004501164A (de)
AT (1) ATE383168T1 (de)
AU (1) AU2001268680A1 (de)
CA (1) CA2414020A1 (de)
DE (1) DE60132343T2 (de)
WO (1) WO2001098346A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
US7432243B2 (en) 2002-04-08 2008-10-07 The Scripps Research Institute Truncated 24kDa basic fibroblast growth factor
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
US20070037872A1 (en) * 2005-06-29 2007-02-15 Mars, Incorporated Inducing peripheral blood vesel vasodilation
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
PT2365828E (pt) 2008-11-07 2014-12-12 Galaxy Biotech Llc Anticorpos monoclonais para o receptor 2 do factor de crescimento de fibroblastos
US8461111B2 (en) * 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2011025865A1 (en) 2009-08-27 2011-03-03 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
EP2558115B1 (de) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Verfahren zur behandlung von stoffwechselstörungen mittels fgf
EP2580710B1 (de) 2010-06-14 2016-11-09 Boston Scientific Neuromodulation Corporation Programmierschnittstelle zur rückenmarks-neuromodulation
CA2828298A1 (en) 2011-03-29 2012-10-04 Boston Scientific Neuromodulation Corporation System and method for leadwire location
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
US8751008B2 (en) 2011-08-09 2014-06-10 Boston Scientific Neuromodulation Corporation Remote control data management with correlation of patient condition to stimulation settings and/or with clinical mode providing a mismatch between settings and interface data
WO2014025624A1 (en) 2012-08-04 2014-02-13 Boston Scientific Neuromodulation Corporation Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices
AU2013308906B2 (en) 2012-08-28 2016-07-21 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US9949738B2 (en) * 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10213214B2 (en) * 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10342551B2 (en) 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
EP3204112A1 (de) 2014-10-07 2017-08-16 Boston Scientific Neuromodulation Corporation Systeme, vorrichtungen und verfahren zur elektrischen stimulation mittels rückkopplung zur einstellung von stimulationsparametern
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
EP3268082B1 (de) 2015-05-26 2019-04-17 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur analyse von elektrischer stimulation und auswahl oder manipulation von aktivierungsvolumina
WO2017003947A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US20160375248A1 (en) 2015-06-29 2016-12-29 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
EP3359252B1 (de) 2015-10-09 2020-09-09 Boston Scientific Neuromodulation Corporation System und verfahren zur kartierung klinischer wirkungen für direktionale stimulationselektroden
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
US10776456B2 (en) 2016-06-24 2020-09-15 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
AU2017341910B2 (en) 2016-10-14 2020-05-14 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
EP3515548B1 (de) 2017-01-03 2021-03-17 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur auswahl von mrt-kompatiblen stimulationsparametern
ES2821752T3 (es) 2017-01-10 2021-04-27 Boston Scient Neuromodulation Corp Sistemas y procedimientos para crear programas de estimulación en base a áreas o volúmenes definidos por el usuario
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
WO2018187090A1 (en) 2017-04-03 2018-10-11 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
EP3615560A4 (de) * 2017-04-26 2020-12-23 University of Cincinnati Zusammensetzungen von fibroblastenwachstumsfaktorliganden und verfahren zur behandlung von patienten mit ischämie-reperfusionstherapie
AU2018301355B2 (en) 2017-07-14 2020-10-01 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
EP3634569A1 (de) 2017-08-15 2020-04-15 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur steuerung der elektrischen stimulation unter verwendung von mehreren stimulationsfeldern
WO2019210202A1 (en) 2018-04-27 2019-10-31 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
WO1996011671A1 (en) 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
ATE279937T1 (de) * 1998-09-03 2004-11-15 Chiron Corp Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Also Published As

Publication number Publication date
EP1324766A2 (de) 2003-07-09
WO2001098346A3 (en) 2003-05-01
US20070135348A1 (en) 2007-06-14
EP1324766B1 (de) 2008-01-09
AU2001268680A1 (en) 2002-01-02
US7186407B2 (en) 2007-03-06
US7541337B2 (en) 2009-06-02
JP2004501164A (ja) 2004-01-15
ATE383168T1 (de) 2008-01-15
DE60132343T2 (de) 2008-12-24
CA2414020A1 (en) 2001-12-27
WO2001098346A2 (en) 2001-12-27
US20020115603A1 (en) 2002-08-22
US20040209817A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
DK0710114T3 (da) Koagulationsfaktor VIII-formulering
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
DE60327771D1 (de) Glp-1 und behandlungsmethode für diabetes
DE69533112T2 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
WO2002022163A1 (fr) Remedes contre des maladies ischemiques
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
EP1894570A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie
RU2130773C1 (ru) Способ лечения саркомы капоши
RU2140270C1 (ru) Способ лечения идиопатического типа саркомы капоши
RU2021130022A (ru) Применение эпидермального фактора роста при лечении диабетической язвы стопы
RU2006142622A (ru) Способ лечения острого инфаркта миокарда
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
JP2006089505A (ja) 虚血性疾患治療剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee